Clinical potential of new antiestrogens

William J Gradishar, V. C. Jordan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

123 Scopus citations


Purpose: Based on the data and clinical experience derived from tamoxifen usage, the properties of an ideal antiestrogen is described that could have applications as a breast cancer preventative agent, long-term adjuvant therapy, or as a treatment for osteoporosis. Each of the new antiestrogens currently being tested is discussed in terms of laboratory development, toxicology, pharmacology, endocrinology, and clinical evaluation. And each new compound is assessed according to the properties of an ideal antiestrogen. Methods: A review of all published reports was facilitated by use of Medline computer searches. Results: Numerous compounds are being evaluated in clinical trials and can be categorized as triphenylethylenes or tamoxifen analogs, pure antiestrogens, and targeted antiestrogens. Several of these compounds may have fewer uterotropic properties and greater effects an maintaining bone density compared with tamoxifen; however, the clinical experience (ie, patient-years of treatment) with any of these compounds is minimal. Conclusion: Although many of these compounds appear promising, further evaluation will be necessary to determine the role these compounds may serve as preventive agents, adjuvant therapies, treatments for advanced disease, or other medical indications such as osteoporosis.

Original languageEnglish (US)
Pages (from-to)840-852
Number of pages13
JournalJournal of Clinical Oncology
Issue number2
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical potential of new antiestrogens'. Together they form a unique fingerprint.

Cite this